Eric Dube, CEO of Travere Therapeutics, discusses the company’s new identity, its experimental therapy sparsentan, and the rare kidney diseases it is being developed to treat.

With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

<p>RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy. </p>

Business

RARECast is a Global Genes podcast hosted by award-winning journalist Daniel Levine. It focuses on the intersection of rare disease with business, science, and policy.

Share With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

Sign up to save your podcasts

With a New Identity, Travere Thearpeutics Seeks to Find Its True Path

With a New Identity, Travere Thearpeutics Seeks to Find Its True Path